Biosimilar Trastuzumab Emtansine Shows Consistent PFS in HER2-Positive Breast Cancer

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27th 2026

By Skylar Jeremias

The US biosimilar market evolves with 90 approvals, significant price drops, and new PBM models enhancing access to cost-effective therapies.

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26th 2026

By Alex Keeton

Biosimilar Competition Linked to Lower Out-of-Pocket Costs for Medicare Patients

January 21st 2026

By Skylar Jeremias

Biosimilar competition significantly reduces out-of-pocket costs for Medicare patients, enhancing affordability for biologic therapies and improving access.

Perceptions Still Play a Central Role in Biosimilar Insulin Switching

January 20th 2026

By Skylar Jeremias

Explore the complexities of insulin biosimilars, their safety, and the impact on diabetes management in global health systems.

Trial Data Support Equivalence of Denosumab Biosimilar in Postmenopausal Osteoporosis

January 16th 2026

By Skylar Jeremias

Denosumab biosimilars enhance treatment access for postmenopausal osteoporosis, demonstrating equivalent efficacy and safety to reference products in recent trials.

What Australia’s Experience Reveals About Biosimilar Adoption and Pricing

January 15th 2026

By Skylar Jeremias

Australia's biosimilar adoption significantly reduces biologic medicine costs, enhancing access while maintaining utilization amid tighter health care budgets.

Eye on Pharma: Global Approvals, Launches, and Strategic Partnerships

January 12th 2026

By Skylar Jeremias

Real-World Study Finds Stable Vision After Switch to Ranibizumab Biosimilar

January 7th 2026

By Skylar Jeremias

Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective solution for long-term management.

Evidence Supports Safe, Effective Switching to Etanercept Biosimilars

January 6th 2026

By Skylar Jeremias

Explore the safety and efficacy of switching to etanercept biosimilars, backed by clinical trials and real-world evidence for chronic inflammatory diseases.

FDA Approves Amneal Denosumab Biosimilars, Capping Year of Market Expansion

January 6th 2026

By Skylar Jeremias

FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving competition and cost savings.